A conserved dendritic-cell regulatory program limits antitumour immunity

Journal: Nature

Published: 2020-03-25

DOI: 10.1038/s41586-020-2134-y

Affiliations: 18

Authors: 23

Go to article
Institutions Share
Precision Immunology Institute, ISMMS, United States of America (USA) 0.25
Tisch Cancer Institute (TCI), ISMMS, United States of America (USA) 0.18
Department of Oncological Sciences, ISMMS, United States of America (USA) 0.09
Department of Thoracic Surgery, ISMMS, United States of America (USA) 0.09
Human Immune Monitoring Core (HIMC), ISMMS, United States of America (USA) 0.07
Department of Genetics and Genomic Sciences, ISMMS, United States of America (USA) 0.04
Oncology Drug Discovery Unit (DDU), United States of America (USA) 0.04
Yale Department of Pharmacology, United States of America (USA) 0.04
NYU Department of Pathology, United States of America (USA) 0.04
NYU Department of Medicine, United States of America (USA) 0.04
Division of Hematology and Medical Oncology, ISMMS, United States of America (USA) 0.03
Yale Department of Neurology, United States of America (USA) 0.02
Yale Department of Immunobiology, United States of America (USA) 0.02
Department of Genetics and Development, CU, United States of America (USA) 0.01
Icahn Institute for Genomics and Multiscale Biology, ISMMS, United States of America (USA) 0.01
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.01
Laboratory of Lymphocyte Dynamics, The Rockefeller University, United States of America (USA) 0.01

Return